Anticorps conjugués dans le cancer broncho-pulmonaire non à petites cellules : où en sommes-nous ?

Q4 Medicine

Revue des Maladies Respiratoires Actualites Pub Date : 2025-10-01 Epub Date: 2025-10-07 DOI:10.1016/S1877-1203(25)00074-6

D. Bruyat , P. Tomasini

{"title":"Anticorps conjugués dans le cancer broncho-pulmonaire non à petites cellules : où en sommes-nous ?","authors":"D. Bruyat , P. Tomasini","doi":"10.1016/S1877-1203(25)00074-6","DOIUrl":null,"url":null,"abstract":"<div><div>Antibody-drug conjugates (ADCs) are an emerging therapeutic class in non-small cell lung cancer (NSCLC). They combine a monoclonal antibody with a potent cytotoxic payload via a cleavable linker, enabling selective tumor targeting with potentially reduced systemic toxicity. This review summarizes the latest data on ADCs in NSCLC, distinguishing targeted approaches based on oncogenic drivers (HER2, c-MET) from those exploiting stable, non-oncogenic membrane antigens (HER3, CEACAM5, B7-H3), as well as antigen-agnostic developments (TROP2). Clinical outcomes vary depending on the target and payload, but support the therapeutic potential of ADCs in difficult-to-treat populations. Specific toxicities, especially interstitial lung disease, require careful monitoring. Future directions include combining ADCs with immunotherapy or tyrosine kinase inhibitors, and optimizing the choice of payloads. Despite their high specificity, ADCs remain sophisticated cytotoxic agents requiring precise pharmacological control. 1877-1203/© 2025 SPLF. Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"17 2","pages":"Pages 2S171-2S179"},"PeriodicalIF":0.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue des Maladies Respiratoires Actualites","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877120325000746","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Antibody-drug conjugates (ADCs) are an emerging therapeutic class in non-small cell lung cancer (NSCLC). They combine a monoclonal antibody with a potent cytotoxic payload via a cleavable linker, enabling selective tumor targeting with potentially reduced systemic toxicity. This review summarizes the latest data on ADCs in NSCLC, distinguishing targeted approaches based on oncogenic drivers (HER2, c-MET) from those exploiting stable, non-oncogenic membrane antigens (HER3, CEACAM5, B7-H3), as well as antigen-agnostic developments (TROP2). Clinical outcomes vary depending on the target and payload, but support the therapeutic potential of ADCs in difficult-to-treat populations. Specific toxicities, especially interstitial lung disease, require careful monitoring. Future directions include combining ADCs with immunotherapy or tyrosine kinase inhibitors, and optimizing the choice of payloads. Despite their high specificity, ADCs remain sophisticated cytotoxic agents requiring precise pharmacological control. 1877-1203/© 2025 SPLF. Published by Elsevier Masson SAS. All rights reserved.

查看原文本刊更多论文

非小细胞肺癌的结合抗体：我们在哪里？

抗体-药物偶联物（adc）是一种新兴的非小细胞肺癌（NSCLC）治疗药物。他们通过可切割的连接体将单克隆抗体与有效的细胞毒性载荷结合起来，实现选择性肿瘤靶向，潜在地降低了全身毒性。本文总结了非小细胞肺癌adc的最新数据，区分了基于致癌驱动因素（HER2, c-MET）和利用稳定的非致癌膜抗原（HER3, CEACAM5, B7-H3）以及抗原不确定发展（TROP2）的靶向方法。临床结果因靶点和有效载荷而异，但支持adc在难以治疗人群中的治疗潜力。特定毒性，特别是间质性肺疾病，需要仔细监测。未来的发展方向包括将adc与免疫疗法或酪氨酸激酶抑制剂联合使用，并优化有效载荷的选择。尽管adc具有很高的特异性，但它们仍然是复杂的细胞毒性药物，需要精确的药理控制。1877-1203/©2025 splf。Elsevier Masson SAS出版。版权所有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊